J Kraft, W Grille, M Appelt, D K Hossfeld, M Eichelbaum, B Koslowski, K Quabeck, R Kuse, T Büchner, W Hiddemann
{"title":"维拉帕米对蒽环类药物引起的心肌病的影响:一项前瞻性多中心试验的初步结果。","authors":"J Kraft, W Grille, M Appelt, D K Hossfeld, M Eichelbaum, B Koslowski, K Quabeck, R Kuse, T Büchner, W Hiddemann","doi":"10.1007/978-3-642-74643-7_103","DOIUrl":null,"url":null,"abstract":"<p><p>Previous investigations in animals and one retrospective study in man suggest that verapamil can prevent anthracycline-induced cardiomyopathy. In the following study, patients with acute myeloid leukemia (AML) treated with double induction and consolidation chemotherapy (AML COOP study 1986, [3]) were randomized in a group with and without accompanying low-dose oral verapamil treatment. Since July 1986, 64 patients have been included. Thirty patients have been evaluated for pre- and posttreatment cardiological investigations. So far, no significant difference in cardiotoxicity has been observed either between the verapamil and nonverapamil group or between the two induction chemotherapy regimens (TAD/TAD - TAD/HAM).</p>","PeriodicalId":12936,"journal":{"name":"Haematology and blood transfusion","volume":"33 ","pages":"566-70"},"PeriodicalIF":0.0000,"publicationDate":"1990-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"14","resultStr":"{\"title\":\"Effects of verapamil on anthracycline-induced cardiomyopathy: preliminary results of a prospective multicenter trial.\",\"authors\":\"J Kraft, W Grille, M Appelt, D K Hossfeld, M Eichelbaum, B Koslowski, K Quabeck, R Kuse, T Büchner, W Hiddemann\",\"doi\":\"10.1007/978-3-642-74643-7_103\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Previous investigations in animals and one retrospective study in man suggest that verapamil can prevent anthracycline-induced cardiomyopathy. In the following study, patients with acute myeloid leukemia (AML) treated with double induction and consolidation chemotherapy (AML COOP study 1986, [3]) were randomized in a group with and without accompanying low-dose oral verapamil treatment. Since July 1986, 64 patients have been included. Thirty patients have been evaluated for pre- and posttreatment cardiological investigations. So far, no significant difference in cardiotoxicity has been observed either between the verapamil and nonverapamil group or between the two induction chemotherapy regimens (TAD/TAD - TAD/HAM).</p>\",\"PeriodicalId\":12936,\"journal\":{\"name\":\"Haematology and blood transfusion\",\"volume\":\"33 \",\"pages\":\"566-70\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"1990-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"14\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Haematology and blood transfusion\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1007/978-3-642-74643-7_103\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Haematology and blood transfusion","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/978-3-642-74643-7_103","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Effects of verapamil on anthracycline-induced cardiomyopathy: preliminary results of a prospective multicenter trial.
Previous investigations in animals and one retrospective study in man suggest that verapamil can prevent anthracycline-induced cardiomyopathy. In the following study, patients with acute myeloid leukemia (AML) treated with double induction and consolidation chemotherapy (AML COOP study 1986, [3]) were randomized in a group with and without accompanying low-dose oral verapamil treatment. Since July 1986, 64 patients have been included. Thirty patients have been evaluated for pre- and posttreatment cardiological investigations. So far, no significant difference in cardiotoxicity has been observed either between the verapamil and nonverapamil group or between the two induction chemotherapy regimens (TAD/TAD - TAD/HAM).
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
